Chengdu Huasun Technology Group Co Ltd
SZSE:000790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (33.1), the stock would be worth ¥4.53 (9% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.3 | ¥4.15 |
0%
|
| 3-Year Average | 33.1 | ¥4.53 |
+9%
|
| 5-Year Average | 30.8 | ¥4.21 |
+1%
|
| Industry Average | 25 | ¥3.42 |
-18%
|
| Country Average | 18.3 | ¥2.5 |
-40%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
Chengdu Huasun Technology Group Co Ltd
SZSE:000790
|
2.6B CNY | 30.3 | -8.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 47.8 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 19.6 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 16.7 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 14.5 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.1 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 12.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 8.2 | 16.4 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Chengdu Huasun Technology Group Co Ltd
Glance View
Chengdu Huasun Technology Group Inc., Ltd. specializes in the research and development, manufacture, and sale of Chinese and Western medicines as well as biopharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 647 full-time employees. The firm primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The firm operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
